The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Summary: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side eff...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Aurélie Bouteau, Henri Estanbouli, Botond Z. Igyártó
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2021-12-01
Edice:	iScience
Témata:	Biological sciences Immunology Biotechnology
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589004221014504
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!